June 2, 2026 · 4 mins read

Network Meta-Analysis of Novel Anti-Seizure Medications Published!

June 1, 2026 · 6 mins read

Cenobamate Recommended for Multi-Scenario Use in the Clinical Practice Guidelines for the Administration of Third-generation Anti-seizure Medications, Emerging as a New Powerful Tool for Epilepsy Treatment

May 8, 2026 · 6 mins read

Yifurui® (cenobamate) Debuts at the 2026 Academic Conference on High-Quality Development of Neurological Diseases & New Advances in Epilepsy Diagnosis and Treatment — Innovation Powers China’s Epilepsy Treatment: Toward a Seizure-Free Era

March 26, 2026 · 6 mins read

Milestone Achievement: First Prescriptions of Cenobamate Tablets (brand name: Xcopri®), Nationwide Fulfilled, Ushering in a New Era of "Seizure Freedom" in Epilepsy Treatment

March 24, 2026 · 5 mins read

Ignis Therapeutics backs the standardization of excessive daytime sleepiness (EDS) diagnosis and treatment, bringing EDS from the shadows into the spotlight

March 20, 2026 · 5 mins read

Ignis Therapeutics Fuels the New Journey of Individualized OSA Diagnosis and Treatment with Novel Wake-Promoting Agent

March 19, 2026 · 6 mins read

Solriamfetol Receives Highest-Grade Recommendation in the 2025 Clinical Practice Guidelines for the Diagnosis and Treatment of Adult Obstructive Sleep Apnea, Ushering in a New Era of Individualized OSA Therapy

March 2, 2026 · 6 mins read

Ignis Therapeutics Announces Publication of Exploratory Analysis: Impact of Solriamfetol on Nocturnal Sleep Quality in Chinese Patients with OSA-EDS from the Phase III Trial

February 26, 2026 · 6 mins read

Good News: China's First EDS Diagnosis and Treatment Column Officially Launched – Novel Wake-Promoting Agents Such as Solriamfetol Take Center Stage

February 25, 2026 · 5 mins read

Solriamfetol Recommended by Chinese Expert Consensus! Dual-Mechanism Wake-Promoting Agent Offers New Option for Patients with Excessive Daytime Sleepiness

January 22, 2026 · 2 mins read

Ignis Therapeutics Advances In-House Pipeline with First Dosing of IGS01 in Healthy Volunteers.

December 25, 2025 · 2 mins read

Ignis Therapeutics' IGS01, a Novel Drug for Levodopa-induced Dyskinesia in Parkinson’s Disease, Approved for Clinical Trials

December 9, 2025 · 4 mins read

Ignis Therapeutics' Solriamfetol Hydrochloride Tablets (翼朗清®) officially approved in China

December 9, 2025 · 6 mins read

New Anti-Seizure Medication cenobamate Tablets（翼弗瑞®）Officially Approved in China, Ushering in a New Chapter for Epilepsy Treatment

November 10, 2025 · 4 mins read

Ignis Therapeutics Announces Publication of Phase III Trial for Solriamfetol in Treating OSA-EDS in China

October 24, 2025 · 4 mins read

Ignis Therapeutics and China Association Against Epilepsy Forge Strategic Partnership to Advance Seizure-Free Futures

September 29, 2025 · 4 mins read

Cenobamate Recommended in Chinese Expert Consensus! Dual-Mechanism Sodium Channel Blocker Offers New Option for Focal Seizures Patients

August 1, 2025 · 4 mins read

Ignis Secures Drug Manufacturing License for Suzhou site

December 10, 2024 · 2 mins read

Ignis Announces CDE Acceptance of New Drug Applications for Two Innovative CNS Therapies

January 12, 2024 · 2 mins read

$160 Million Total Investment! Today, Ignis Therapeutics Commences Construction.

November 1, 2023 · 1 min read

Center for Excellence in Molecular Cell Science, CAS, and Ignis Therapeutics Forge Collaboration Agreement.

January 26, 2022 · 2 mins read

Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction.